Company intelligence / Profile preview

Toron

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Toron (also known as Toron Bio) is an early-stage biotechnology company dedicated to the development of next-generation precision immunology therapies. The company utilizes a proprietary platform to identify and target specific immune pathways that drive the progression of cancer and various autoimmune disorders. By focusing on high-specificity modulation of the immune system, Toron aims to overcome the limitations of current systemic treatments and deliver more effective, targeted therapies. Founded by experienced industry leaders, the company is currently advancing its research programs through the pre-clinical stage.

Therapeutic areas: OncologyImmunology
Modalities: Small moleculeBiologic
Industry: Biotech

Beyond the preview

Go deeper on Toron.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Toron.

Explore the full profile